Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer

被引：0
|
作者：
Kikuchi, Y., Sr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Kouta, H. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Kikuchi, R. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Takano, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Kita, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Kudoh, K. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Aoki, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Sugiyama, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Isonishi, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Ohki Mem Kikuchi Canc Clin Women, Tokorozawa, Saitama, Japan
[2] Natl Def Med Coll, Tokorozawa, Saitama 359, Japan
[3] Teikyo Univ, Sch Med, Tokyo 173, Japan
[4] Nishisaitama Cent Hosp, Tokorozawa, Saitama, Japan
[5] Keio Univ, Sch Med, Tokyo, Japan
[6] Iwate Med Univ, Morioka, Iwate 020, Japan
[7] Jikei Univ, Sch Med, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5547
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients
    Gorumlu, G.
    Kucukzeybek, Y.
    Kemal-Gul, M.
    Karaca, B.
    Cosan-Terek, M.
    Karabulut, B.
    Sanli, U. A.
    Akman, L.
    Ozsaran, A.
    Dikmen, Y.
    Uslu, R.
    JOURNAL OF BUON, 2008, 13 (03): : 349 - 352
  • [2] Pegylated liposomal doxorubicin (PLD) in heavily pretreated epithelial ovarian cancer patients
    Gorumlu, Gurbuz
    Kucukzeybek, Yuksel
    Karabulut, Bulent
    Terek, Mustafa C.
    Uslu, Ruchan
    Sanli, Ulus A.
    Akman, Levent
    Ozsaran, Aydin
    Dikmen, Yilmaz
    Goker, Erdem
    ANNALS OF ONCOLOGY, 2006, 17 : 172 - 172
  • [3] Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
    Kudoh, Kazuya
    Takano, Masashi
    Kouta, Hiroko
    Kikuchi, Ryoko
    Kita, Tsunekazu
    Miyamoto, Morikazu
    Watanabe, Akio
    Kato, Masafumi
    Goto, Tomoko
    Kikuchi, Yoshihiro
    GYNECOLOGIC ONCOLOGY, 2011, 122 (02) : 233 - 237
  • [4] Pegylated liposomal Doxorubicin in Recurrent Ovarian Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (11)
  • [5] Carboplatin, pegylated liposomal Doxorubicin, and Bevacizumab in Ovarian Cancer
    Gappa, Birgit
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (08)
  • [6] Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma
    Katsaros, D
    Oletti, MV
    de la Longrais, IAR
    Ferrero, A
    Celano, A
    Fracchioli, S
    Donadio, M
    Passera, R
    Cattel, L
    Bumma, C
    ANNALS OF ONCOLOGY, 2005, 16 (02) : 300 - 306
  • [7] Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
    Chura, Justin C.
    Van Iseghem, Kelin
    Downs, Levi S., Jr.
    Carson, Linda F.
    Judson, Patricia L.
    GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : 326 - 330
  • [8] Pegylated liposomal doxorubicin (Caelyx™) in recurrent ovarian cancer
    Stebbing, J
    Gaya, A
    CANCER TREATMENT REVIEWS, 2002, 28 (02) : 121 - 125
  • [9] Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan
    Almubarak, Mohammed
    Newton, Michael
    Altaha, Ramin
    JOURNAL OF ONCOLOGY, 2008, 2008
  • [10] Effect of weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with heavily pretreated ovarian cancer
    Ikeda, Yuji
    Kikuchi, Yoshihiro
    Takano, Masashi
    Goto, Tomoko
    Kouta, Hiroko
    Sasaki, Naoki
    Kudoh, Kazuya
    Oda, Katsutoshi
    Nagasaka, Tsuneki
    Kita, Tsunekazu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345